

Maria Majdan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4476247/publications.pdf>

Version: 2024-02-01

112
papers

2,239
citations

394421

19
h-index

243625

44
g-index

121
all docs

121
docs citations

121
times ranked

3235
citing authors

#	ARTICLE	IF	CITATIONS
1	Respiratory involvement in antineutrophil cytoplasmic antibody-associated vasculitides: a retrospective study based on POLVAS registry. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.8	1
2	Biological impact of iberdomide in patients with active systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1136-1142.	0.9	13
3	The value of anti-CarP and anti-PAD4 as markers of rheumatoid arthritis in ACPA/RF negative rheumatoid arthritis patients. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2198986.	2.7	14
4	Systemic Inflammatory Parameters in Patients with Elderly-Onset Rheumatoid Arthritis (EORA) and Young-Onset Rheumatoid Arthritis (YORA) – An Observational Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 1204.	2.4	11
5	Sicca syndrome in the same family – the importance of anti-Ro60, anti-Ro52 and anti-La antibody profiling in Sjögren’s syndrome. <i>Reumatologia</i> , 2021, 59, 260-264.	1.1	0
6	The prevalence and significance of anti-PM/Scl antibodies in systemic sclerosis. <i>Annals of Agricultural and Environmental Medicine</i> , 2021, 28, 189-192.	1.0	6
7	Subphenotypes of ANCA-associated vasculitis identified by latent class analysis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 129, 62-68.	0.8	1
8	Plasma micro-RNA-22 is associated with disease activity in well-established rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.8	0
9	Subphenotypes of ANCA-associated vasculitis identified by latent class analysis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 62-68.	0.8	4
10	The relationship of ADAMTSL2 and LRPAP1 gene methylation level with rheumatoid arthritis activity.. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.8	0
11	Haematological abnormalities in systemic sclerosis. <i>Reumatologia</i> , 2020, 58, 162-166.	1.1	6
12	Nephrotic syndrome in the course of type 1 diabetes mellitus and systemic lupus erythematosus with secondary antiphospholipid syndrome – diagnostic and therapeutic problems. A case-based review. <i>Reumatologia</i> , 2020, 58, 331-334.	1.1	2
13	ANCA-associated vasculitis patients treated in Polish intensive care units – retrospective characteristics based on the POLVAS registry. <i>Anaesthesiology Intensive Therapy</i> , 2020, 52, 281-286.	1.0	2
14	Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2020, 8, 963-974.	10.7	348
15	The Relationship between Hematological Markers of Systemic Inflammation (Neutrophil-To-Lymphocyte, Platelet-To-Lymphocyte, Lymphocyte-To-Monocyte Ratios) and Ultrasound Disease Activity Parameters in Patients with Rheumatoid Arthritis. <i>Journal of Clinical Medicine</i> , 2020, 9, 2760.	2.4	31
16	Differential approach to peripheral blood cell ratios in patients with systemic lupus erythematosus and various manifestations. <i>Rheumatology International</i> , 2020, 40, 1625-1629.	3.0	10
17	Hypermethylation of the miR-155 gene in the whole blood and decreased plasma level of miR-155 in rheumatoid arthritis. <i>PLoS ONE</i> , 2020, 15, e0233897.	2.5	12
18	Peptidyl Arginine Deiminase Type 4 Gene Promoter Hypo-Methylation in Rheumatoid Arthritis. <i>Journal of Clinical Medicine</i> , 2020, 9, 2049.	2.4	10

#	ARTICLE	IF	CITATIONS
19	Treatment and its side effects in ANCA-associated vasculitides – Study based on POLVAS registry data. <i>Advances in Medical Sciences</i> , 2020, 65, 156-162.	2.1	13
20	Methylation Pattern of the SOCS3 and IL6R Promoters in Rheumatoid Arthritis. <i>International Journal of Inflammation</i> , 2020, 2020, 1-7.	1.5	0
21	CLINICAL AND SEROLOGICAL PARAMETERS OF PROGRESSION AND PROGNOSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS – A STATE OF THE ART REVIEW. <i>Wiadomości Lekarskie</i> , 2020, 73, 1528-1532.	0.3	2
22	Clinical consequences of the presence of anti-RNA Pol III antibodies in systemic sclerosis. <i>Postepy Dermatologii i Alergologii</i> , 2020, 37, 909-914.	0.9	6
23	The presence of particular criteria and non-criteria antiphospholipid antibodies in patients with uterine malignancies. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 1037-1042.	0.4	2
24	Clinical and serological parameters of progression and prognosis in patients with systemic sclerosis - a state of the art review. <i>Wiadomości Lekarskie</i> , 2020, 73, 1528-1532.	0.3	1
25	Urticarial rash, fever, and arthritis: A case of refractory Adult-onset Still's disease with good response to tocilizumab. <i>Dermatologic Therapy</i> , 2019, 32, e13041.	1.7	2
26	Factors associated with quality of life in systemic sclerosis: a cross-sectional study. <i>Quality of Life Research</i> , 2019, 28, 3347-3354.	3.1	29
27	Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-associated Vasculitis: A Randomized Controlled Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 952-963.	5.6	82
28	Gender Differences in Cardiovascular Risk Profile in Rheumatoid Arthritis Patients with Low Disease Activity. <i>BioMed Research International</i> , 2019, 2019, 1-7.	1.9	13
29	Diastolic dysfunction in rheumatoid arthritis patients with low disease activity. <i>Clinical Rheumatology</i> , 2019, 38, 1131-1137.	2.2	13
30	IRF5 promoter methylation as a new potential marker of rheumatoid arthritis. <i>Polish Archives of Internal Medicine</i> , 2019, 129, 370-376.	0.4	5
31	LATE-ONSET SJÅ-GRENÆ™S SYNDROM. <i>Wiadomości Lekarskie</i> , 2019, 72, 1687-1690.	0.3	1
32	Reasons for diagnostic delays of axial spondyloarthritis. <i>Wiadomości Lekarskie</i> , 2019, 72, 1607-1610.	0.3	3
33	Efficacy and safety of etanercept in psoriasis and psoriatic arthritis in the PRESTA study: analysis in patients from Central and Eastern Europe. <i>Journal of Dermatological Treatment</i> , 2018, 29, 8-12.	2.2	8
34	Tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the Polish Society for Rheumatology. <i>Reumatologia</i> , 2018, 56, 203-211.	1.1	21
35	Cardiovascular system changes in rheumatoid arthritis patients with continued low disease activity. <i>Rheumatology International</i> , 2018, 38, 1207-1215.	3.0	22
36	Prospective assessment of cardiovascular risk parameters in patients with rheumatoid arthritis. <i>Cardiovascular Ultrasound</i> , 2018, 16, 18.	1.6	12

#	ARTICLE	IF	CITATIONS
37	Overlap syndromes in systemic sclerosis. <i>Postepy Dermatologii I Alergologii</i> , 2018, 35, 246-250.	0.9	12
38	Satisfaction and discontent of Polish patients with biological therapy of rheumatic diseases: results of a multi-center questionnaire study. <i>Reumatologia</i> , 2018, 56, 140-148.	1.1	7
39	Î2-microglobulin as a marker of systemic lupus erythematosus activity. <i>Advances in Clinical and Experimental Medicine</i> , 2018, 27, 379-382.	1.4	13
40	Efficacy and safety of golimumab as add-on therapy to standard disease-modifying antirheumatic drugs: Results of the GO-MORE study in the Polish population. <i>Advances in Clinical and Experimental Medicine</i> , 2018, 27, 493-499.	1.4	1
41	Anti-CCP antibodies and rheumatoid factor in systemic sclerosis: Prevalence and relationships with joint manifestations. <i>Advances in Clinical and Experimental Medicine</i> , 2018, 27, 1253-1257.	1.4	8
42	Zesp³Å, hemofagocytowy indukowany terapiÄ... hormonalnÄ... â€“ studium przypadku klinicznego. <i>Acta Haematologica Polonica</i> , 2018, 49, 151-156.	0.3	0
43	Epigenetic aspects of rheumatoid arthritis: contribution of non-coding RNAs. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 46, 724-731.	3.4	28
44	Kidney involvement in antiphospholipid syndrome â€“ current diagnostic and management problems. <i>Reumatologia</i> , 2017, 55, 213-214.	1.1	5
45	Influence of antiphospholipid antibody positivity on glomerular filtration rate markers in a group of systemic sclerosis patients â€“ a 24-month observation. <i>Central-European Journal of Immunology</i> , 2017, 2, 161-166.	1.2	1
46	Status of etoricoxib in the treatment of rheumatic diseases. Expert panel opinion. <i>Reumatologia</i> , 2017, 55, 290-297.	1.1	9
47	Coexistence of diabetes mellitus type 1 with diffuse systemic sclerosis â€“ case report and literature review. <i>Reumatologia</i> , 2017, 2, 104-107.	1.1	2
48	Differential expression of programmed death 1 (PD-1) on CD4+ and CD8+ T cells in rheumatoid arthritis and psoriatic arthritis. <i>Polish Archives of Internal Medicine</i> , 2017, 127, 815-822.	0.4	11
49	Glucose tolerance disorders during treatment with glucocorticoids in patients with inflammatory diseases of the musculoskeletal system â€“ based on the analysis of data from the literature and own research results. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2017, 71, 0-0.	0.1	0
50	Epigenetic determinants in rheumatoid arthritis: the influence of DNA methylation and histone modifications. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2017, 71, 0-0.	0.1	0
51	Comparison of clinical and serological parameters in female and male patients with systemic sclerosis. <i>Reumatologia</i> , 2016, 53, 315-320.	1.1	9
52	Presence of organâ€‘specific antibodies in patients with systemic sclerosis. <i>Polish Archives of Internal Medicine</i> , 2016, 126, 862-869.	0.4	7
53	Assessment of education requirements for patients with rheumatoid arthritis, based on the Polish version of the Educational Needs Assessment Tool (Pol-ENAT), in the light of some health problems â€“ A cross-sectional study. <i>Annals of Agricultural and Environmental Medicine</i> , 2016, 23, 361-367.	1.0	8
54	The present and future status of internal medicine in Poland and in the world. <i>Polish Archives of Internal Medicine</i> , 2016, 126, 939-941.	0.4	0

#	ARTICLE	IF	CITATIONS
55	Prevalence of selected organ-specific autoantibodies in rheumatoid arthritis and primary Sjögren's syndrome patients. <i>Reumatologia</i> , 2015, 53, 61-68.	1.1	5
56	Response to: Comment on "Serum Amyloid A as a Marker of Persistent Inflammation and an Indicator of Cardiovascular and Renal Involvement in Patients with Rheumatoid Arthritis" Mediators of Inflammation, 2015, 2015, 1-1.	3.0	0
57	Clinical picture of late-onset systemic lupus erythematosus in a group of Polish patients. <i>Polish Archives of Internal Medicine</i> , 2015, 125, 538-544.	0.4	7
58	The occurrence of antibodies against <i>Legionella pneumophila</i> in patients with autoimmune rheumatic diseases. <i>Polish Archives of Internal Medicine</i> , 2015, 125, 749-754.	0.4	2
59	Recommendations for diagnosis and treatment Selected principles of proper education of women with rheumatic diseases in respect of pregnancy planning. <i>Reumatologia</i> , 2014, 1, 49-56.	1.1	2
60	Recommendations for diagnosis and treatment Recommendations for obstetric management and principles of cooperation between rheumatologists and obstetricians in systemic connective tissue disease patients. <i>Reumatologia</i> , 2014, 1, 38-48.	1.1	0
61	Review Carbohydrate metabolism disorders in patients with rheumatoid arthritis and ankylosing spondylitis " impact of the severity of the inflammatory process and disease activity. <i>Reumatologia</i> , 2014, 1, 62-68.	1.1	1
62	Certolizumab pegol " new option in the treatment of psoriatic arthritis. <i>Reumatologia</i> , 2014, 3, 181-188.	1.1	1
63	Fertility, pregnancy planning, and pharmacotherapy during the pregnancy, postpartum and breastfeeding period in patients with rheumatoid arthritis and other inflammatory arthropathies. <i>Reumatologia</i> , 2014, 52, 7-21.	1.1	2
64	Recommendations for diagnosis and treatment Fertility, pregnancy planning, and treatment during the pregnancy, postpartum and breastfeeding period in patients with antiphospholipid syndrome. <i>Reumatologia</i> , 2014, 1, 30-37.	1.1	0
65	Carbohydrate metabolism disorders in patients with rheumatoid arthritis and ankylosing spondylitis " impact of treatment. <i>Reumatologia</i> , 2014, 2, 129-135.	1.1	0
66	Recommendations for diagnosis and treatment Fertility, pregnancy and breastfeeding in systemic lupus erythematosus patients. <i>Reumatologia</i> , 2014, 1, 22-29.	1.1	0
67	Serum Amyloid A as a Marker of Persistent Inflammation and an Indicator of Cardiovascular and Renal Involvement in Patients with Rheumatoid Arthritis. <i>Mediators of Inflammation</i> , 2014, 2014, 1-7.	3.0	75
68	Antiphospholipid antibodies during 6-month treatment with infliximab: A preliminary report. <i>Medical Science Monitor</i> , 2014, 20, 1227-1231.	1.1	7
69	Serological profile of patients with systemic sclerosis. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2014, 68, 987-991.	0.1	17
70	Kynurenic Acid in Synovial Fluid and Serum of Patients with Rheumatoid Arthritis, Spondyloarthropathy, and Osteoarthritis. <i>Journal of Rheumatology</i> , 2013, 40, 903-909.	2.0	15
71	Induction of response with etanercept "methotrexate therapy in patients with moderately active rheumatoid arthritis in Central and Eastern Europe in the PRESERVE study. <i>Clinical Rheumatology</i> , 2013, 32, 1275-1281.	2.2	15
72	Editorial paper Gout " new diagnostic and therapeutic options. <i>Reumatologia</i> , 2013, 1, 1-8.	1.1	1

#	ARTICLE	IF	CITATIONS
73	Identification of latent tuberculosis infection in rheumatic patients under consideration for treatment with anti-TNF-Î± agents. Archives of Medical Science, 2013, 1, 112-117.	0.9	13
74	Adalimumab treatment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis in therapeutic programmes â€” personal experience. Reumatologia, 2013, 1, 9-14.	1.1	2
75	Remission in lupus nephritis â€” report of three cases. Reumatologia, 2013, 1, 85-88.	1.1	1
76	Recommendations for diagnosis and treatment Chronic inflammation of the joints â€” the transition from pediatric rheumatologist to adult rheumatologist. Recommendations of the Panel of Experts on National Consultant in the field of rheumatology (recommendations in the context of the conditions) Tj ETQq0 0 0 rgt /Overlock 10 Tf	1.1	1
77	Catastrophic antiphospholipid syndrome in a patient with systemic lupus erythematosus. Reumatologia, 2013, 1, 73-76.	1.1	0
78	Etanercept in a therapeutic program for the treatment of rheumatoid arthritis and ankylosing spondylitis â€” 7 yearsâ€™ personal experience. Reumatologia, 2013, 1, 15-19.	1.1	0
79	Selected problems of biologic therapy in rheumatoid arthritis patients â€” pregnancy during therapy.. Reumatologia, 2013, 1, 93-95.	1.1	0
80	Rheumatic manifestations in hepatitis C virus infection.. Reumatologia, 2013, 1, 96-99.	1.1	0
81	Effectiveness and safety of the use of rituximab in patients with active rheumatoid rthritis â€” 5 yearsâ€™ personal observations. Reumatologia, 2013, 1, 20-25.	1.1	1
82	Characteristics of Polish patients with systemic lupus erythematosus obtained from SESAME registry. Activity of the disease, degree of impairment, and availability of social care. Reumatologia, 2013, 5, 332-341.	1.1	2
83	Pregnancy in patients with systemic lupus erythematosus.. Reumatologia, 2013, 1, 77-79.	1.1	1
84	Selected problems of biologic therapy in rheumatoid arthritis patients â€” inefficacy of several biologic therapies.. Reumatologia, 2013, 1, 89-92.	1.1	0
85	Central nervous system lupus â€” three different manifestations of the disease. Reumatologia, 2013, 1, 80-84.	1.1	0
86	Relationship between rheumatoid arthritis activity and antithyroid antibodies. Polish Archives of Internal Medicine, 2013, 123, 394-400.	0.4	15
87	Kynurenic acid content in anti-rheumatic herbs. Annals of Agricultural and Environmental Medicine, 2013, 20, 800-2.	1.0	11
88	Patient's global assessment of disease activity and patient's assessment of general health for rheumatoid arthritis activity assessment: are they equivalent?. Annals of the Rheumatic Diseases, 2012, 71, 1942-1949.	0.9	59
89	Letter to the Editor ZiarniniakowatoÅ z zapaleniem naczyÅ, â€” nowa nazwa ziarniniakowatoÅci Wegenera i potrzeba jej upowszechnienia. Reumatologia, 2012, 6, 541-542.	1.1	2
90	Efficacy of radiosynoviorthesis and its impact on chosen inflammatory markers. Rheumatology International, 2012, 32, 2339-2344.	3.0	7

#	ARTICLE	IF	CITATIONS
91	Determinants of discordance in patients' and physicians' rating of rheumatoid arthritis disease activity. <i>Arthritis Care and Research</i> , 2012, 64, 206-214.	3.4	144
92	The Relationship Between Carotid Intima-Media Thickness and the Activity of Rheumatoid Arthritis. <i>Journal of Clinical Rheumatology</i> , 2011, 17, 249-255.	0.9	25
93	Amino-terminal pro-brain natriuretic peptide as a prognostic marker in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2011, 30, 61-69.	2.2	11
94	Antibodies against cyclic citrullinated peptide don't decrease after 6 months of infliximab treatment in refractory rheumatoid arthritis. <i>Rheumatology International</i> , 2011, 31, 1439-1443.	3.0	2
95	Adiponectin and leptin serum concentrations in patients with rheumatoid arthritis. <i>Rheumatology International</i> , 2010, 30, 731-737.	3.0	54
96	Influence of long-term leflunomide treatment on serum amyloid concentration in rheumatoid arthritis patients. <i>Pharmacological Reports</i> , 2010, 62, 719-725.	3.3	9
97	Antiphospholipid antibodies and kidney involvement in patients with systemic sclerosis. <i>Clinical Rheumatology</i> , 2009, 28, 955-959.	2.2	18
98	Parthenolide Inhibits Proliferation of Fibroblast-Like Synoviocytes In Vitro. <i>Inflammation</i> , 2008, 31, 281-285.	3.8	14
99	Leptin serum levels in rheumatoid arthritis patients: relation to disease duration and activity. <i>Rheumatology International</i> , 2008, 28, 585-591.	3.0	77
100	Coexistence of five autoimmune diseases: diagnostic and therapeutic difficulties. <i>Rheumatology International</i> , 2008, 28, 919-923.	3.0	22
101	Remission and rheumatoid arthritis: Data on patients receiving usual care in twenty-four countries. <i>Arthritis and Rheumatism</i> , 2008, 58, 2642-2651.	6.7	156
102	Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. <i>Arthritis Research and Therapy</i> , 2008, 10, R30.	3.5	387
103	Radiation synovectomy with 90Y colloid in the therapy of recurrent knee joint effusions in patients with inflammatory joint diseases. <i>Rheumatology International</i> , 2007, 27, 729-734.	3.0	26
104	Nephrotic syndrome as a clinical manifestation of systemic sclerosis. <i>Rheumatology International</i> , 2007, 27, 1087-1089.	3.0	8
105	Antiproliferative activity of parthenolide against three human cancer cell lines and human umbilical vein endothelial cells. <i>Pharmacological Reports</i> , 2007, 59, 233-7.	3.3	27
106	Kynurenic acid, an endogenous constituent of rheumatoid arthritis synovial fluid, inhibits proliferation of synoviocytes in vitro. <i>Rheumatology International</i> , 2006, 26, 422-426.	3.0	39
107	Effect of glutamate receptor antagonists and antirheumatic drugs on proliferation of synoviocytes in vitro. <i>European Journal of Pharmacology</i> , 2006, 535, 95-97.	3.5	16
108	Peritoneal dialysis with solutions low in glucose degradation products is associated with improved biocompatibility profile towards peritoneal mesothelial cells. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 917-924.	0.7	66

#	ARTICLE	IF	CITATIONS
109	Genetic Determination of TNF and Myeloperoxidase Production in Dialyzed Patients with Diabetic Nephropathy. <i>Renal Failure</i> , 2004, 26, 633-639.	2.1	11
110	Polymorphisms of Tumor Necrosis Factor and Myeloperoxidase Genes in Patients with Chronic Renal Failure on Peritoneal Dialysis. <i>Molecular Diagnosis and Therapy</i> , 2003, 7, 175-180.	1.1	9
111	The relationship of ADAMTSL2 and LRPAP1 gene methylation level with rheumatoid arthritis activity. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.8	1
112	Serum Calprotectin – a NET Product – as a Biomarker of Disease Activity in Patients with Systemic Lupus Erythematosus: A Single-Center Case-Control Study from Poland. <i>Medical Science Monitor</i> , 0, 28, .	1.1	1